MOLECULAR DISTRIBUTION OF HUMAN ADRENERGIC RECEPTORS
人肾上腺素能受体的分子分布
基本信息
- 批准号:6638338
- 负责人:
- 金额:$ 39.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-09-01 至 2005-03-31
- 项目状态:已结题
- 来源:
- 关键词:adrenergic receptor affinity labeling cell line chimeric proteins deoxyribonuclease I gel mobility shift assay gene deletion mutation genetic promoter element genetic regulatory element hormone regulation /control mechanism human tissue in situ hybridization laboratory rat liver cells nucleic acid sequence phosphorylation receptor expression receptor sensitivity second messengers species difference transcription factor transfection
项目摘要
The overall long term objective of this research is to determine
mechanisms underlying regulation of human adrenergic receptors (ARs).
Within this context, this competitive renewal seeks to investigate two
specific aspects of AR regulation using the alpha1aAR as a model--1)
mechanisms underlying species specific tissue distribution of AR
subtypes, and 2) mechanisms underlying agonist-induced regulation of the
human alpha1aAR. During the last grant period we demonstrated AR
subtype specific and species-dependent tissue expression. Although 5'-
regulatory sequences have been shown to bind tissue specific
transcription factors, this information is limited to detailed analysis
of only a few tissues. Since comparative information regarding human
and rat tissue distribution of alpha1AR subtypes was obtained during the
last grant period, and other studies in our laboratory (not directly
related to this grant) resulted in cloning and characterization of 6.2kb
5'UTR of the human alpha1aAR gene, we are in a unique position to test
the hypothesis that species specific tissue expression (rat versus
human) of ARs results from differences in 5'-regulatory gene sequences.
This will be accomplished by cloning the rat alpha1aAR 5'UTR and
comparing rat versus human reporter construct expression in tissues of
interest (rat neonatal myocytes, hepatoma cell lines, SK-N-MC cells);
DNase I assays using nuclei isolated from fresh human and rat tissues
of interest (heart, mammary artery, liver) will also be utilized for
these studies. During the previous grant period we also examined the
influence of disease and age on human cardiovascular AR subtype
expression. Hypertension, congestive heart failure, and aging all
increase circulating catecholamine levels, hence a natural progression
from our previous studies is to examine the response of ARs to agonist
exposure. The alpha1aAR is unique in that agonist exposure in a rat
neonatal myocyte model results in upregulation and continued signaling,
while alpha1b and alpha1dARs undergo concurrent downregulation and
desensitization; this pathway has been shown to be important in
alpha1AR-mediated myocardial hypertrophy and raises the question of
whether alpha1aARs are capable of undergoing desensitization. In
preliminary studies we find that rapid (less than 5 min) acute partial
desensitization of human alpha1aARs occurs (signaling remains 50 percent
of naive receptor after 30 min of agonist exposure). Therefore we plan
to test the hypothesis that alpha1aAR acute partial desensitization
occurs via mechanisms distinct from other ARs, enabling persistent
signaling in the presence of agonist. These studies will utilize a
hemagglutinin (HA)-tagged human alpha1aAR and COOH-terminal deletion
mutant to characterize agonist-dependent (norepinephrine [NE]) and
agonist-independent (phorbol ester [PMA]) pathways, as well as study the
role of receptor phosphorylation (using immunoprecipitation of HA tagged
receptors) and sequestration (whole cell binding assays). Mutation of
putative phosphorylation sites and chimeric alpha1a/alpha1bARs will then
be used to further define mechanisms underlying this process. Extensive
training in molecular pharmacology of ARs, experience in protein
biochemistry of desensitization, experience in cloning 5'UTRs and
characterizing the human alpha1aAR gene, as well as availability of
several human alpha1aAR reporter constructs already in the laboratory,
places us in a unique position to elucidate mechanisms underlying
regulation of ARs using the alpha1aAR as a model. Results from these
studies should facilitate therapeutic interventions (e.g. enhanced human
tissue targeting for gene therapy) as well as understanding of
mechanisms underlying cardiovascular diseases.
这项研究的总体长期目标是确定
项目成果
期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genetics and patient outcome after cardiac surgery: unravelling translational findings.
心脏手术后的遗传学和患者结果:揭示转化结果。
- DOI:10.1093/bja/aer347
- 发表时间:2011
- 期刊:
- 影响因子:9.8
- 作者:Schwinn,DA
- 通讯作者:Schwinn,DA
Alpha1a-Adrenoceptor Genetic Variant Triggers Vascular Smooth Muscle Cell Hyperproliferation and Agonist Induced Hypertrophy via EGFR Transactivation Pathway.
- DOI:10.1371/journal.pone.0142787
- 发表时间:2015
- 期刊:
- 影响因子:3.7
- 作者:Gradinaru I;Babaeva E;Schwinn DA;Oganesian A
- 通讯作者:Oganesian A
A critical period for the role of thyroid hormone in development of renal alpha-adrenergic receptors.
甲状腺激素在肾α-肾上腺素能受体发育中发挥作用的关键时期。
- DOI:10.1203/00006450-199707000-00015
- 发表时间:1997
- 期刊:
- 影响因子:0
- 作者:Tan,JP;Seidler,FJ;Schwinn,DA;Page,SO;Slotkin,TA
- 通讯作者:Slotkin,TA
Acute agonist-mediated desensitization of the human alpha 1a-adrenergic receptor is primarily independent of carboxyl terminus regulation: implications for regulation of alpha 1aAR splice variants.
人α1a-肾上腺素能受体的急性激动剂介导的脱敏主要独立于羧基末端调节:对α1aAR剪接变体调节的影响。
- DOI:10.1074/jbc.m111762200
- 发表时间:2002
- 期刊:
- 影响因子:0
- 作者:Price,RReyn;Morris,DanielP;Biswas,Gopa;Smith,MichaelP;Schwinn,DebraA
- 通讯作者:Schwinn,DebraA
Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues.
- DOI:
- 发表时间:1995
- 期刊:
- 影响因子:0
- 作者:D. Schwinn;G. Johnston;S. O. Page;M. J. Mosley;K. Wilson;N. Worman;S. Campbell;M. Fidock;L. Furness;D. Parry-Smith
- 通讯作者:D. Schwinn;G. Johnston;S. O. Page;M. J. Mosley;K. Wilson;N. Worman;S. Campbell;M. Fidock;L. Furness;D. Parry-Smith
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Debra Anne Schwinn其他文献
Debra Anne Schwinn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Debra Anne Schwinn', 18)}}的其他基金
PHARMACOGENETICS OF CX(1A)-ADRENOCEPTORS IN HYPERTENSION
CX(1A)-肾上腺素受体在高血压中的药物遗传学
- 批准号:
7198453 - 财政年份:2005
- 资助金额:
$ 39.3万 - 项目类别:
Genetics Myocardial Adverse Outcomes/Graft Failure-CABG
遗传学心肌不良后果/移植失败-CABG
- 批准号:
6822382 - 财政年份:2004
- 资助金额:
$ 39.3万 - 项目类别:
B-Adrenergic Receptor Antagonists in Cardiac Surgery
B-肾上腺素能受体拮抗剂在心脏手术中的应用
- 批准号:
6974005 - 财政年份:2004
- 资助金额:
$ 39.3万 - 项目类别:
Genetics Myocardial Adverse Outcomes/Graft Failure-CABG
遗传学心肌不良后果/移植失败-CABG
- 批准号:
6914963 - 财政年份:2004
- 资助金额:
$ 39.3万 - 项目类别:
Pharmacogenetics of a(1a)-Adrenoceptors in Hypertension
高血压中 a(1a)-肾上腺素受体的药物遗传学
- 批准号:
6974016 - 财政年份:2004
- 资助金额:
$ 39.3万 - 项目类别:
Genetics Myocardial Adverse Outcomes/Graft Failure-CABG
遗传学心肌不良后果/移植失败-CABG
- 批准号:
7086875 - 财政年份:2004
- 资助金额:
$ 39.3万 - 项目类别:
ROLE OF B ADRENERGIC RECEPTOR ANTAGONISTS IN CARDIAC SURGERY PATIENTS
B 肾上腺素能受体拮抗剂在心脏手术患者中的作用
- 批准号:
6565334 - 财政年份:2001
- 资助金额:
$ 39.3万 - 项目类别:
相似海外基金
Development of Affinity Labeling Approaches for Protein Identification
蛋白质鉴定亲和标记方法的开发
- 批准号:
554025-2020 - 财政年份:2020
- 资助金额:
$ 39.3万 - 项目类别:
University Undergraduate Student Research Awards
Design of a novel affinity labeling probe exhibiting fluorescence and luminescence
一种新型亲和标记探针的设计,具有荧光和发光功能
- 批准号:
16K17930 - 财政年份:2016
- 资助金额:
$ 39.3万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Affinity Labeling the Dopamine Transporter Active Site
多巴胺转运蛋白活性位点的亲和标记
- 批准号:
6731145 - 财政年份:2003
- 资助金额:
$ 39.3万 - 项目类别:
Affinity Labeling the Dopamine Transporter Active Site
多巴胺转运蛋白活性位点的亲和标记
- 批准号:
6868946 - 财政年份:2003
- 资助金额:
$ 39.3万 - 项目类别:
Affinity Labeling the Dopamine Transporter Active Site
多巴胺转运蛋白活性位点的亲和标记
- 批准号:
6579786 - 财政年份:2003
- 资助金额:
$ 39.3万 - 项目类别:
SGER: X-ray Crystallographic and Affinity Labeling Analysis of the Structure of Rat Epididymal N-Acetyl-B-D-hexosaminidase: Insight into the Catalytic Mechanism
SGER:大鼠附睾 N-乙酰基-B-D-氨基己糖苷酶结构的 X 射线晶体学和亲和标记分析:深入了解催化机制
- 批准号:
9804595 - 财政年份:1998
- 资助金额:
$ 39.3万 - 项目类别:
Standard Grant
Affinity Labeling of Nucleotide Sites in Proteins
蛋白质中核苷酸位点的亲和标记
- 批准号:
9728202 - 财政年份:1998
- 资助金额:
$ 39.3万 - 项目类别:
Continuing Grant
AFFINITY LABELING OF GLUTATHIONE S TRANSFERASES
谷胱甘肽 S 转移酶的亲和标记
- 批准号:
2654163 - 财政年份:1996
- 资助金额:
$ 39.3万 - 项目类别:
AFFINITY LABELING OF GLUTATHIONE S TRANSFERASES
谷胱甘肽 S 转移酶的亲和标记
- 批准号:
2871848 - 财政年份:1996
- 资助金额:
$ 39.3万 - 项目类别:
AFFINITY LABELING OF GLUTATHIONE S TRANSFERASES
谷胱甘肽 S 转移酶的亲和标记
- 批准号:
2109965 - 财政年份:1996
- 资助金额:
$ 39.3万 - 项目类别:














{{item.name}}会员




